A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang; Wentao Li; Dubravka Drabek; Nisreen M.A. Okba; Rien van Haperen; Albert D.M.E. Osterhaus; Frank J.M. van Kuppeveld; Bart L. Haagmans; Frank Grosveld; Berend Jan Bosch

doi:10.1038/s41467-020-16256-y

A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang
, Wentao Li
, Dubravka Drabek
, Nisreen M.A. Okba
, Rien van Haperen
, Albert D.M.E. Osterhaus
, Frank J.M. van Kuppeveld
, Bart L. Haagmans
, Frank Grosveld
, Berend Jan Bosch

Utrecht University
Erasmus University Rotterdam
Harbour BioMed
University of Veterinary Medicine Hannover, Foundation

Research output: Contribution to journal › Article › peer-review

864 Scopus citations

Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

Original language	English
Article number	2251
Journal	Nature Communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-16256-y
State	Published - 1 Dec 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41467-020-16256-y

Cite this

@article{cc620d8dfdcc4181b27b6ddc0cbb541f,

title = "A human monoclonal antibody blocking SARS-CoV-2 infection",

abstract = "The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.",

author = "Chunyan Wang and Wentao Li and Dubravka Drabek and Okba, \{Nisreen M.A.\} and \{van Haperen\}, Rien and Osterhaus, \{Albert D.M.E.\} and \{van Kuppeveld\}, \{Frank J.M.\} and Haagmans, \{Bart L.\} and Frank Grosveld and Bosch, \{Berend Jan\}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-16256-y",

language = "英语",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - A human monoclonal antibody blocking SARS-CoV-2 infection

AU - Wang, Chunyan

AU - Li, Wentao

AU - Drabek, Dubravka

AU - Okba, Nisreen M.A.

AU - van Haperen, Rien

AU - Osterhaus, Albert D.M.E.

AU - van Kuppeveld, Frank J.M.

AU - Haagmans, Bart L.

AU - Grosveld, Frank

AU - Bosch, Berend Jan

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

AB - The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

UR - https://www.scopus.com/pages/publications/85084214161

U2 - 10.1038/s41467-020-16256-y

DO - 10.1038/s41467-020-16256-y

M3 - 文章

C2 - 32366817

AN - SCOPUS:85084214161

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2251

ER -

A human monoclonal antibody blocking SARS-CoV-2 infection

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this